PT3672954T - Compostos e respectivos sais e sua utilização no tratamento de doenças - Google Patents

Compostos e respectivos sais e sua utilização no tratamento de doenças

Info

Publication number
PT3672954T
PT3672954T PT187860697T PT18786069T PT3672954T PT 3672954 T PT3672954 T PT 3672954T PT 187860697 T PT187860697 T PT 187860697T PT 18786069 T PT18786069 T PT 18786069T PT 3672954 T PT3672954 T PT 3672954T
Authority
PT
Portugal
Prior art keywords
diseases
salts
compounds
treatment
methods
Prior art date
Application number
PT187860697T
Other languages
English (en)
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of PT3672954T publication Critical patent/PT3672954T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
PT187860697T 2017-08-21 2018-08-20 Compostos e respectivos sais e sua utilização no tratamento de doenças PT3672954T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762548301P 2017-08-21 2017-08-21
SE1730225 2017-08-24

Publications (1)

Publication Number Publication Date
PT3672954T true PT3672954T (pt) 2025-09-29

Family

ID=63840976

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187860697T PT3672954T (pt) 2017-08-21 2018-08-20 Compostos e respectivos sais e sua utilização no tratamento de doenças

Country Status (22)

Country Link
US (3) US11345693B2 (pt)
EP (2) EP3672954B1 (pt)
JP (2) JP7297738B2 (pt)
KR (1) KR102692233B1 (pt)
CN (2) CN111132976B (pt)
AU (1) AU2018321546B2 (pt)
BR (1) BR112020003477A2 (pt)
CA (1) CA3071644A1 (pt)
DK (1) DK3672954T3 (pt)
ES (1) ES3042110T3 (pt)
FI (1) FI3672954T3 (pt)
HU (1) HUE073569T2 (pt)
IL (1) IL272444B (pt)
LT (1) LT3672954T (pt)
MX (1) MX2020001757A (pt)
PL (1) PL3672954T3 (pt)
PT (1) PT3672954T (pt)
RS (1) RS67273B1 (pt)
SG (1) SG11202001062XA (pt)
SI (1) SI3672954T1 (pt)
WO (1) WO2019040107A1 (pt)
ZA (1) ZA202001717B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040107A1 (en) * 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES
US11440884B2 (en) 2017-08-21 2022-09-13 Acadia Pharmaceuticals Inc. Compounds, salts thereof and methods for treatment of diseases
PL3741744T3 (pl) * 2019-05-22 2022-04-25 Zakłady Farmaceutyczne "Polpharma" S.A. Farmaceutyczny produkt pośredni do wytwarzania pimawanseryny
EP3906969A4 (en) * 2019-06-12 2023-11-22 Tao Pharmaceutical (Suzhou) Co., Ltd. ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF
CN115677723B (zh) * 2020-01-21 2024-06-04 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN113214141B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其制备和应用
CN113214231B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其医疗应用
WO2021147818A1 (zh) * 2020-01-21 2021-07-29 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN115605202B (zh) 2020-03-26 2025-10-28 盐野义制药株式会社 具有血清素受体结合活性的芳香族杂环衍生物
CN111548257B (zh) * 2020-05-28 2022-11-15 安道麦马克西姆有限公司 一种（4-异丙氧基-2-甲基）苯基异丙基酮的制备方法
CN114728933B (zh) * 2020-07-22 2023-06-16 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
WO2022145408A1 (ja) * 2020-12-28 2022-07-07 塩野義製薬株式会社 セロトニン受容体結合活性を有する環状アミン誘導体
CN113292484B (zh) * 2021-06-04 2022-11-15 沈阳药科大学 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用
ES3066682T3 (en) * 2021-08-11 2026-05-14 Curadev Pharma Pvt Ltd Small molecule urea derivatives as sting antagonists
CN121318920A (zh) * 2022-08-03 2026-01-13 绿叶嘉奥制药石家庄有限公司 5-ht2a受体反向激动剂及其制备方法和应用
WO2024067304A1 (zh) * 2022-09-28 2024-04-04 瀚远医药有限公司 一种具有Sigma2和5HT2A抑制活性的化合物及用途
WO2024105007A1 (en) * 2022-11-15 2024-05-23 Samsara Therapeutics Inc. Autophagy inducing compounds and uses thereof
KR20260048603A (ko) 2023-08-02 2026-04-10 아카디아 파마슈티칼스 인코포레이티드 세로토닌-수용체 5-ht와 관련된 질환의 치료에서 사용하기 위한 3-(4-사이클로-프로폭시벤질)-1-(2,4-다이플루오로벤질)-1-(1-메틸피페리딘-4-일)유레아
WO2025162237A1 (zh) * 2024-02-02 2025-08-07 绿叶嘉奥制药石家庄有限公司 一种5-ht2a受体反向激动剂的盐型、晶型及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1998A (en) 1841-03-12 Refrigerator
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
KR100879647B1 (ko) 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
JP2005533813A (ja) * 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ，インコーポレーテッド セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
US7875609B2 (en) * 2005-11-25 2011-01-25 Galapagos Sasu Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them
TW200831517A (en) 2006-12-15 2008-08-01 Astrazeneca Ab Chemical compounds
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
KR100878446B1 (ko) 2007-06-07 2009-01-13 일동제약주식회사 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
NO2200610T3 (pt) * 2007-09-21 2018-06-09
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2010111353A1 (en) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
AU2014369053B2 (en) 2013-12-20 2019-03-14 Institute For Drug Discovery, Llc Substituted amino triazoles, and methods using same
CN104844502B (zh) 2015-06-05 2018-07-31 齐鲁师范学院 一种匹莫范色林的制备方法
CN107848972B (zh) 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
CN105481757A (zh) 2015-12-25 2016-04-13 北京康立生医药技术开发有限公司 一种哌马色林的制备方法
WO2019040107A1 (en) * 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES
US11440884B2 (en) 2017-08-21 2022-09-13 Acadia Pharmaceuticals Inc. Compounds, salts thereof and methods for treatment of diseases

Also Published As

Publication number Publication date
RS67273B1 (sr) 2025-10-31
EP3672954A1 (en) 2020-07-01
CN111132976A (zh) 2020-05-08
SG11202001062XA (en) 2020-03-30
CN111132976B (zh) 2023-08-22
NZ761678A (en) 2025-05-30
BR112020003477A2 (pt) 2020-08-25
FI3672954T3 (fi) 2025-10-16
CN117466803A (zh) 2024-01-30
JP7628578B2 (ja) 2025-02-10
DK3672954T3 (da) 2025-10-20
JP2020531505A (ja) 2020-11-05
MX2020001757A (es) 2020-09-07
KR20200043409A (ko) 2020-04-27
WO2019040107A1 (en) 2019-02-28
IL272444A (en) 2020-03-31
US20250197385A1 (en) 2025-06-19
AU2018321546A1 (en) 2020-02-27
JP2023116691A (ja) 2023-08-22
IL272444B (en) 2021-12-01
ES3042110T3 (en) 2025-11-18
CA3071644A1 (en) 2019-02-28
EP4635568A3 (en) 2025-12-03
AU2018321546B2 (en) 2022-09-08
LT3672954T (lt) 2025-10-27
KR102692233B1 (ko) 2024-08-05
JP7297738B2 (ja) 2023-06-26
US20220298151A1 (en) 2022-09-22
SI3672954T1 (sl) 2025-11-28
EP3672954B1 (en) 2025-08-13
US20200270239A1 (en) 2020-08-27
EP4635568A2 (en) 2025-10-22
ZA202001717B (en) 2025-04-30
PL3672954T3 (pl) 2025-11-12
HUE073569T2 (hu) 2026-01-28
US11345693B2 (en) 2022-05-31
US12139477B2 (en) 2024-11-12

Similar Documents

Publication Publication Date Title
IL272444A (en) Compounds, their salts and methods for treating diseases
ZA202006746B (en) Methods of treatment
IL264049A (en) Compounds, preparations and methods for treating the disease
ZA201800641B (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
IL264156A (en) Compounds, preparations and methods for treating the disease
IL253945A0 (en) kdm1a inhibitors to treat the disease
EP3212233A4 (en) Combination therapy for treatment of disease
HUE060671T2 (hu) Eljárás fibrotikus betegségek kezelésére
IL253244A0 (en) Methods for treating retinal diseases
PL3504187T3 (pl) Stosowanie pridopidyny w leczeniu zaburzeń czynnościowych
PT3273955T (pt) Tratamento de doenças respiratórias
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
PL3210973T3 (pl) Związki heteroarylowe do leczenia chorób oczu
EP3340974A4 (en) METHODS OF TREATING DISEASES
IL253847A0 (en) Methods of treating diseases
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
PT3619204T (pt) Compostos para o tratamento de doenças respiratórias
IL259381B (en) Mirabegron for the treatment of retinal diseases
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
SG11202005278PA (en) Compounds for treating eye diseases and methods thereof
GB201500555D0 (en) Method and device for the treatment of diseases
EP3094330A4 (en) Treatment of crohn&#39;s disease using low doses of laquinimod
HUE065063T2 (hu) Brómhexin a fájdalom kezelésére